Handelsavisen
prelaunch
Companies Healthcare TNZTP.IS
TN
TNZTP.IS Borsa Istanbul Healthcare Facilities & Services

Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS

$25,60
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
28,4 %
ROE
8,7 %
Net margin
20,3 %
Debt / equity
0,05
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Tapdi Oksijen provides pharmaceutical and healthcare services, primarily generating revenue through the production and distribution of oxygen-related medical products and healthcare education services.

Business. Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS (TNZTP.IS) is a healthcare services and equipment company primarily engaged in healthcare facilities and services, with activities including pharmaceuticals. The firm operates on a service-revenue model within the broader healthcare sector. Specific details regarding operating segments and geographic presence are not disclosed. The company is listed on the Borsa Istanbul.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
8,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TNZTP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TNZTP.IS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS (TNZTP.IS) is a healthcare services and equipment company primarily engaged in healthcare facilities and services, with activities including pharmaceuticals. The firm operates on a service-revenue model within the broader healthcare sector. Specific details regarding operating segments and geographic presence are not disclosed. The company is listed on the Borsa Istanbul.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong capital structure with a debt-to-equity ratio of 0.05, indicating a low reliance on debt financing. However, its liquidity position is rated as medium, with negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints. The company's return on equity (ROE) of 8.69% and return on assets (ROA) of 7.27% are both above the industry median, reflecting efficient use of equity and assets to generate returns.

    Profitability is robust, with a gross profit margin of 40.98% and an operating margin of 28.37%, both of which are strong indicators of cost control and pricing power. The company's net income margin of 20.29% is also well above the industry median, suggesting a healthy bottom line. These metrics align with the industry's preferred focus on operating efficiency and asset utilization.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts, which could impact revenue stability. The absence of segment or geographic breakdowns in the financial data limits the ability to assess risk distribution across different markets or product lines.

    Looking ahead, the company is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the following year. The free cash flow of 614.91 million TRY supports reinvestment or shareholder returns, though the negative operating cash flow of -443.55 million TRY raises concerns about short-term cash generation.

    The risk assessment highlights a medium liquidity risk due to the negative net cash position after debt, which could constrain operational flexibility. The dilution risk is rated as low, with no significant dilution expected in the near term. However, the company's reliance on free cash flow for growth may necessitate future capital raising, which could introduce dilution pressure.

    Recent filings and transcripts do not provide specific details on strategic initiatives or major events, but the company's financial performance suggests a focus on maintaining profitability and managing debt levels. The absence of recent major announcements or regulatory actions indicates a relatively stable operating environment.

    Key takeaways
    • The company has a strong ROE and ROA, indicating efficient capital use and asset management.
    • A low debt-to-equity ratio suggests a conservative capital structure.
    • Negative net cash after debt raises liquidity concerns despite a medium liquidity risk rating.
    • Revenue concentration in a single segment increases exposure to market-specific risks.
    • Free cash flow is positive, supporting potential reinvestment or shareholder returns.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $25,60
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $8.01B
    Net cash
    -$390.1M
    Current ratio
    1.6
    Debt / equity
    0.1
    ROA
    7.3%
    ROE
    8.7%
    Cash conversion
    -64.0%
    CapEx / revenue
    -8.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin28,4 %Best in class
    Net Margin20,3 %Best in class
    ROE8,7 %Above median
    Capex / Rev-8,1 %Below median
    D/E0,05Above P75
    Cash Conv-0,64Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TNZTP.ISCanonical
    Borsa Istanbul · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage